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Objective—Increased caffeine intake is associated with a lower risk of Parkinson’s disease (PD)
and is neuroprotective in mouse models of PD. However, in a prior study, an exploratory analysis
showed that, in patients taking creatine, caffeine intake was associated with a faster rate of
progression. In the current study we investigated the association of caffeine with the rate of
progression of PD and the interaction of this association with creatine intake.
Methods—Data were analyzed from a large Phase 3 placebo-controlled clinical study of creatine
as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45
movement disorders centers across the United States and Canada. A total of 1,741 PD subjects
participated in the primary clinical study, and caffeine intake data were available for 1,549 of
these subjects. The association of caffeine intake with rate of progression of PD as measured by
the change in the total Unified Parkinson Disease Rating Scale (UPDRS) score, and the interaction
of this association with creatine intake, were assessed.

Author Manuscript

Results—Caffeine intake was not associated with the rate of progression of PD in the main
analysis, but higher caffeine intake was associated with significantly faster progression among
subjects taking creatine.
Conclusions—This is the largest and longest study conducted to date that addresses the
association of caffeine with the rate of progression of PD. These data indicate a potentially
deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.

INTRODUCTION

Author Manuscript
Author Manuscript

Caffeine has a dose-depended inverse association with the risk of developing Parkinson’s
disease (PD)(1, 2)Caffeine is an antagonist at adenosine A2a receptors, although a recent
study suggested that it may act as an A2a inverse agonist(3). Both caffeine and other more
specific A2a receptor antagonists are neuroprotective in toxin-induced PD animal models(4).
Furthermore, mice lacking the A2a receptor are protected against dopaminergic
neurodegeneration induced by mutant α-synuclein(5). These data have led to the hypothesis
that caffeine may have a neuroprotective effect in PD. As a preliminary test of this
hypothesis, we previously analyzed data from 2 Phase 2 futility-design clinical studies of
potential disease-modifying therapies in PD. Arms in the studies included creatine,
minocycline and placebo in one study (FS1)(6); and coenzyme Q10, GPI-1485 (an
immunophilin ligand) and placebo in the other(FS2)(7). A caffeine intake questionnaire was
completed by participating subjects. Unexpectedly, among subjects randomized to creatine,
increasing levels of caffeine intake were associated with significantly faster progression of
PD as measured by the change in the total UPDRS score, whereas there was no consistent
association of caffeine with progression in other treatment groups(8). We sought to replicate
and extend this surprising but potentially important observation by analyzing the association
of caffeine intake with the rate of progression of PD as a substudy of a large multicenter
double-blind, placebo-controlled Phase 3 clinical study of creatine as a potentially diseasemodifying therapy in PD, the “Large Long Term Study” (LS1)(9).
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METHODS
Study subjects and the LS1 study

Author Manuscript

A total of 1,741 early PD subjects (diagnosed within 5 years) already treated with
dopaminergic therapy were enrolled in LS1 and randomized 1:1 to creatine 10 grams per
day or placebo. Subjects were recruited from 45 sites in the US and Canada. All subjects
were within 5 years from diagnosis and were receiving dopaminergic therapy (levodopa or a
dopamine agonist) for at least 90 days but no more than 2 years at the time of recruitment
into the study. This study was sponsored by the National Institute of Neurological Disorders
and Stroke (NINDS). Details of the study design and characteristics of participants have
been published elsewhere(9, 10). The goal was to follow all subjects for a minimum of 5
years; however, a preplanned interim analysis conducted when half of the subjects had
reached the 5-year time point suggested that creatine was unlikely to meet the pre-specified
threshold for significant slowing of clinical disease progression, and the study was
terminated early. All study procedures were approved by institutional review boards at each
participating site.
Caffeine questionnaire
A total of 1,549 subjects completed a caffeine intake questionnaire that had been used
previously in the Futility Study (FS)1 study(8). This questionnaire focused primarily on
intake of caffeinated beverages during the prior week. The majority of subjects who
completed the questionnaire did so at the 18-month time point of the study. In this analysis
we did not take into account those who did not complete a questionnaire, but data comparing
characteristics of those who completed or did not complete the caffeine questionnaire are
presented.

Author Manuscript

Statistical methods

Author Manuscript

The primary outcome measure was the total Unified Parkinson’s Disease Rating Scale
(UPDRS) score during all years of follow-up, with baseline UPDRS included as a covariate.
For all analyses (baseline and follow-up) we defined “total UPDRS” as the sum of scores for
a participant for UPDRS parts I-III. The UPDRS was selected a priori for this analysis as
this measure was used in our prior study based on data from the FS1 and FS2 studies(8). We
sought to determine if we could replicate the results of that prior study in the current
analysis of data from the larger and longer duration LS1. The distribution of daily caffeine
consumption was zero-inflated and highly skewed to the right. A log and square root
transformation did not lead to normally distributed data due to the high percentage of zero
values. Therefore, caffeine was analyzed as a categorical variable, with subjects split into
high and low caffeine intake groups. The low caffeine group was defined as subjects with
daily caffeine intake less than or equal to 300 mg. The high caffeine group had caffeine
intakes greater than 300 mg per day. This cutoff of 300mg has been used in previous studies
Ascherio, 2001 #645;Fernandez-Duenas, 2014 #3085;Ross, 2000 #644;Schwarzschild, 2003
#3082} of health-related impacts of caffeine consumption.
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Baseline characteristics were compared for the low (N=1,288) and high (N=261) caffeine
groups. P-values from Wilcoxon and Chi-square tests were obtained for continuous and
binary variables respectively.
To assess the effect of caffeine while adjusting for other covariates and interactions, a mixed
model was used with site as random effect. The response variable was the annual total
UPDRS score from year 1 to 5. The mixed model used all available longitudinal annual
measurements of UPDRS, assuming the correlation structure of multiple measurements
within each individual to be Heterogeneous Auto Regression One (ARH1). The Auto
Regression (AR1) structure assumes the correlation of yearly UPDRS is mainly related to
measurements in neighboring years and the relationships decrease as the time between
measurements increase. The heterogeneous structure relaxed the variance assumption for
each measurement and allows a different variance at each time point.

Author Manuscript

Models were fit by SAS PROC MIXED using REML method. Fixed effect parameters were
estimated for every model. REML in PROC MIXED accommodates data that are missing at
random. Missing data in our sample were mostly due to loss of follow-up, drop-outs or
deaths. Loss of follow-up here refers to loss due to early trial closure; drop-outs appeared to
be unrelated to caffeine and thus were considered missing at random as well. Death could be
considered missing at random only if the reason for death was not related to caffeine
consumption. There was no association of caffeine intake with cardiac death in this data set,
a cause of death that in theory might have been related to caffeine, so death also was
considered missing at random.

Author Manuscript

We fit the basic model using caffeine category (high versus low) along with other variables
of clinical interest, which included treatment group, age at enrollment, years since
enrollment (year), baseline UPDRS score, and gender as main effects. Treatment by caffeine
interaction, treatment by gender interaction, and year interactions with treatment, caffeine,
age, gender and baseline UPDRS, as well as the three way interactions of
treatment*caffeine*year, treatment*gender*year, caffeine*gender*year were tested for their
significance by interaction plots and Wald Test p values. The final basic model included
significant main effects at the 0.05 level and significant interactions at the 0.1 level.

Author Manuscript

Next we assessed the confounding and modifying effect of covariates that might associate
with caffeine or disease progression. First, the pairwise correlation was computed between
continuous variables. In order to avoid multi-colinearity, variables that were highly
correlated were not both kept in the model. Each covariate was added to the basic model to
test its influence on disease progression. Their interaction with caffeine also was tested by
two-way and three-way interactions with time. Wald Test with p values less than 0.05 for
main effects and 0.1 for interaction terms were used to select variables for the final model.
Main effects remained in the model if any interactions including this main effect were
significant. Final model diagnostics checked the normality of the residual plot and the
pattern of residual versus predictors. If a significant interaction of treatment (creatine versus
placebo) by caffeine group was detected, separate models for treatment groups were built to
assess the effect of caffeine in the different groups.
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RESULTS
Baseline characteristics of the 1,549 subjects who completed the caffeine questionnaire and
for the 192 subjects who did not are shown in Table 1. Most baseline characteristics were
not significantly different between these 2 groups. Subjects who did not provide caffeine
intake data had significantly higher baseline Beck Depression Inventory (BDI) scores,
UDPRS scores and levodopa dose equivalents, suggesting that depressive symptoms or
more severe PD symptoms may have reduced the chances of completing the caffeine
questionnaire.

Author Manuscript

The distribution of caffeine intake is shown in Figure 1. Table 2 compares baseline
characteristics for subjects in the high and low caffeine groups. Uric acid levels were
compared due to the association of uric acid levels with rate of progression of PD(11), and
to reports that high caffeine intake may be associated with lower uric acid levels(12).
Median uric acid levels and median body mass index (BMI) were significantly higher in
subjects in the high caffeine group, whereas days since diagnosis at the time of study entry
was lower in the high caffeine group. A significantly lower percentage of female subjects
was present in the high versus low caffeine group.

Author Manuscript

In the final model, there was a significant 3-way interaction between treatment group
(creatine versus placebo), caffeine category (high versus low) and years since enrollment in
assessing the association with total UPDRS score (i.e. rate of progression). Therefore, the
placebo and creatine groups were analyzed separately. For the placebo group, caffeine and
rate of progression did not interact. In contrast, there was a significant interaction between
caffeine and rate of progression for the creatine group, with high caffeine intake being
associated with more rapid progression (Figure 2 and Table 3; p = 0.002). Uric acid was not
statistically significant in either model (p-values >0.1), and so was not included in the model
based on our model selection criteria.
The lack of an interaction between caffeine and rate of progression in the placebo group is
consistent with a similar analysis in a previously published study(8). However, it remains
possible that even modest levels of caffeine below the 300mg cutoff used for our primary
analysis might be associated with slowing of clinical progression of PD, which would limit
our ability to detect an association of caffeine with rate of progression using the 300mg
threshold. To address this possibility, we conducted an additional post-hoc analysis of
caffeine and rate of progression comparing subjects with very low caffeine intake (<25mg/
day; n=662) to those in the high caffeine group (>300mg/day; n=261), and again there was a
lack of a significant interaction in the placebo group.

Author Manuscript

An interesting possibility raised by these results is that the association of high caffeine
intake with a faster rate of progression among subjects taking creatine may have masked a
protective effect of creatine among subjects with low levels of caffeine intake. However,
subgroup analyses restricted to subjects in the low caffeine group (<300mg/day; n=1,288) or
the very low caffeine group (<25mg/day; n=662) revealed no significant associations of
treatment (creatine versus placebo) and rate of progression of PD.
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DISCUSSION
Epidemiological data indicate a dose-dependent association of caffeine intake with the risk
of PD(1, 2). Furthermore, caffeine is neuroprotective in animal models of PD(4), raising the
possibility that caffeine also may have neuroprotective effects in PD patients. Therefore, we
predicted that high caffeine intake would be associated with slower progression of PD.
Contrary to this prediction, we found that among patients randomized to take creatine,
higher caffeine intake was associated with a significantly faster rate of progression of PD,
whereas there was no significant association detected for caffeine with the rate of
progression among placebo subjects.

Author Manuscript
Author Manuscript

In a prior study of 2 smaller clinical cohorts, we similarly found no association of caffeine
intake with the rate of progression of PD(8) over 12 months. This prior study also
unexpectedly identified a significant association of caffeine with a faster rate of progression
among subjects taking creatine, but this finding was not considered to be definitive due to
the small number of subjects in that study (n = 64 subjects on creatine), the lack of an a
priori prediction of this result, and a result of borderline significance. In contrast, the current
study included clinical progression data for up to 5 years from 1,549 subjects. Furthermore,
based on the results of the prior study, for the current study we specifically hypothesized a
priori that higher caffeine intake would be associated with faster progression among subjects
taking creatine. Indeed, we confirmed this result (p = 0.002), suggesting a deleterious
interaction between caffeine and creatine with respect to the rate of clinical progression of
PD. Although data on the frequency of combined use of creatine and caffeine in the general
population are not available, caffeine use is common, with 17% of PD subjects in the LS1
study having intakes greater than 300mg/day. Creatine supplements also are common among
certain populations, with one study suggesting that 50% of high school senior football
players using creatine supplements(13). However, the prevalence of creatine use in the
general PD population is unknown. The current study was restricted to PD patients and so it
remains unknown if there may be a deleterious interaction between creatine and caffeine use
in people who do not have PD or in a younger population.

Author Manuscript

The LS1 trial of creatine ended early for futility based on a pre-planned interim analysis.
Our observation of a faster rate of progression among subjects with high levels of caffeine
intake raises the interesting possibility that creatine may actually have had a beneficial effect
among subjects with lower levels of caffeine intake, but this effect was negated by the
deleterious effect among subjects with high levels of caffeine intake. However, no
significant association of creatine with rate of progression of PD even was detected when
considering only those subjects in the low caffeine group (<300mg/day) or only those
subjects with very low caffeine intake (<25mg/day).
Recent data have suggested that caffeine may have a symptomatic benefit in PD(14). We
observed a similar mean levodopa equivalent dose at baseline among subjects in the low and
high caffeine groups, and a nonsignificant trend towards lower baseline UPDRS scores in
the high caffeine group. However, because this study was not randomized with respect to
caffeine intake, the lower baseline UPDRS scores do not necessarily imply a symptomatic
benefit from caffeine. In any case, a symptomatic effect of caffeine on PD symptoms should
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not complicate our analysis of the association of caffeine intake with progression of PD
unless either the level of caffeine intake changes during the study, or if the magnitude of the
symptomatic benefit of caffeine changes as the disease progresses.

Author Manuscript

The potential mechanism by which caffeine and creatine may negatively interact with
respect to the rate of progression of PD is not addressed in the current study. A prior study
suggested that caffeine completely negates the effects of creatine on muscle contraction(15,
16), potentially by counteracting the creatine associated facilitation of calcium uptake by the
sarcoplasmic reticulum(16). It is interesting to note that high caffeine intake was associated
with a mild but significant increase in uric acid levels (Table 2). This contrasts with prior
reports of an association of caffeine with lower serum uric acid levels(17), and suggests that
the relationship between caffeine intake and uric acid level may be different in PD patients
compared to the general population. Uric acid is an antioxidant and high uric acid levels
have been associated with a lower risk of PD and with a slower rate of progression of
PD(18). However, despite the higher uric acid levels in the high caffeine group, we did not
detect an association of high caffeine use with a slower rate of progression of PD.

Author Manuscript
Author Manuscript

This study has several strengths, including a large population of PD patients with detailed
clinical assessments by movement disorders specialists over several years, as well as
availability of data on caffeine intake for a majority of the subjects. There also are
limitations. Caffeine data were collected at only one time point during the study, and this
was 18 months after baseline. Therefore, our analyses could not account for potential
changes in levels of caffeine intake over the course of the study. In our previously published
study a repeat caffeine questionnaire was administered after 1 year, and this demonstrated
that the level of caffeine intake was relatively stable (changed by less than 25%) in ~90% of
subjects(8). However, the percentage of subjects with changes in caffeine intake likely is
greater in the current study due to its longer duration. Not all participants provided caffeine
data, although baseline differences between those who provided data and those who did not
were minimal. The most important drawback is that subjects were not randomized or
blinded with respect to caffeine intake. It is possible that other factors that are associated
with caffeine use could influence these results. Relating to this point, data on smoking were
not collected for the LS1 subjects. There is an association with caffeine and tobacco use(19).
This raises the possibility that the associations with caffeine reported in this study may
reflect an influence of tobacco use. However, the current results replicate our prior report
that caffeine use is inversely associated with rate of clinical progression of PD in subjects
taking creatine, and results in the prior study remained significant after adjusting for
smoking(8). Similarly, in a study by Hamza et al identifying GRIN2A genotype as a
modifier of the influence of caffeine on the risk of PD, the results were similar before and
after adjusting for smoking(4). Furthermore, the frequency of smoking is low in PD
patients(19), and so this issue is likely to be relevant to only a small percentage of LS1
subjects. A case control study of over 500 PD patients and a similar number of controls at
movement disorders centers in the US revealed that only 3.6% of PD subjects smoked
cigarettes and also had significant caffeine intake(20)(Tanner et al., unpublished data).
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An additional possible limitation is the retrospective self-reported nature of the caffeine
questionnaire, although studies on caffeine intake quantification have documented the
validity of self-report methods(21).
In conclusion, these data show no association of caffeine with the rate of clinical progression
of PD except in the group of participants taking creatine where progression was increased.
This study was not randomized or blinded with respect to caffeine intake. For this reason,
and based on the strength of epidemiological and preclinical data suggesting that caffeine
may have neuroprotective effects in PD, further study of the potential neuroprotective
effects of caffeine and other A2a receptor antagonists remains warranted. Given the lack of
any benefits of creatine for PD patients in the LS1 study, as well as the possibility of a
deleterious effect when combined with caffeine, it remains prudent to recommend against
creatine supplementation for PD patients.

Author Manuscript
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Figure 1. Distribution of daily caffeine intake

Distribution of daily caffeine intake among the 1,549 subjects for whom caffeine intake data
were available. The mean intake was 134.8mg per day
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Figure 2. Caffeine and total UPDRS

Author Manuscript

2a) Loess plot for total UPDRS over year by caffeine categories. The y axis used the fitted
value of total UPDRS from the creatine subgroup model (Table 3). The smoothing
parameters are automatically selected by SAS PROC SGPLOT.
2b) Interaction plot of treatment by caffeine categories over total UPDRS. The y axis is the
fitted UPDRS from the final model for the whole population. Smoothing parameter is 0.3 in
SAS PROC SGPLOT.
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Table1

Author Manuscript

Baseline characteristics of those who completed the caffeine questionnaire to those who did not.
Caffeine data
available
N=1549

Caffeine data
NOT available
N=192

Levodopa Equiv.

Median

300.0

389.5

Dose at Baseline

SD

242.31

255.49

IQ range*

225.0

275.0

Beck Depression

Median

6.0

6.5

Index

SD

5.40

6.49

IQ range

6.0

9.0

Median

5.0

5.1

SD

1.34

1.38

IQ range

1.8

1.6

Median

27.0

27.7

SD

7.07

5.64

IQ range

5.9

5.5

Median

62.0

64.0

SD

9.39

11.42

IQ range

12.0

14.0

Median

483.0

470.5

SD

401.0

347.36

IQ range

496.0

482.5

Median

24.0

29.0

SD

11.08

13.10

IQ range

15.0

17.5

Freq

553

65

%

35.70

33.85

Freq

776

98

%

50.10

51.04

Uric Acid

Author Manuscript

Body Mass Index

Age at Enrollment

Days since Diagnosis

Author Manuscript

UPDRS Baseline

Female

Treatment(Creatine)

1

p-value

<0.001**

<0.007**

0.51

0.12

0.15

0.78

<0.0001***

0.61

0.80

1

Continuous variables are tested using Wilcoxon Two-Sample Test; Binary variables are tested using Chi-square test.

*

IQ range is interquartile range.
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Author Manuscript

Baseline characteristics of subjects in the low (≤300mg) and high (>300mg) caffeine intake groups
Low Caffeine
N=1288

High Caffeine
N=261

Levodopa Equiv.

Median

300.0

300.0

Dose at Baseline

SD

236.73

267.74

IQ range*

225

300.0

Beck Depression

Median

6.0

5.0

Index

SD

5.45

5.11

IQ range

6.0

6.0

Median

5.0

5.3

SD

1.34

1.34

IQ range

1.9

1.8

Median

26.7

27.8

SD

7.37

5.31

IQ range

5.9

5.3

Median

62.0

61.0

SD

9.42

9.24

IQ range

13.0

13.0

Median

493.0

412.0

SD

404.42

379.06

IQ range

492

480

Median

25.0

22.5

SD

11.17

10.55

IQ range

15.0

15.0

Freq

490

63

%

38.04

24.14

Freq

647

129

%

50.23

49.43

Uric Acid

Author Manuscript

Body Mass Index

Age at Enrollment

Days since Diagnosis

Author Manuscript

UPDRS Baseline

Female

Treatment(Creatine)

2

p-value
0.38

0.12

0.04**

<0.0001***

0.23

0.003**

<0.07*

<0.0001***

0.81

2

Continuous variables are tested using Wilcoxon Two-Sample Test; Binary variables are tested using Chi-square test.

*

IQ range is interquartile range.
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Table 3

Author Manuscript

Final models for the subgroup of subjects randomized to creatine (N=765) and to placebo (N=770)
Effect for Creatine Sub-Group

Estimate

Standard Error

Intercept

3.54

2.84

Baseline UPDRS

DF

t Value

Pr > |t|

49

1.25

0.22

3028

Author Manuscript

0.76

0.03

24.91

<.0001***

+Years since enrollment

----

----

----

----

+Caffeine category

----

----

----

----

−1.40

0.67

3028

−2.08

0.04**

Age

0.01

0.04

3028

0.24

0.814

Beck Depression Inventory (BDI)

0.24

0.06

3028

3.91

<.0001***

Years since enrollment*Age

0.07

0.02

3028

4.40

<.0001***

Years since enrollment*Caffeine category

1.29

0.42

3028

3.07

0.002**

Intercept

9.81

2.80

48

3.50

0.001

Baseline UPDRS

0.75

0.03

3067

25.58

<.0001***

----

----

----

----

<.0001***

Caffeine Category

−0.21

0.73

3067

−0.29

0.77

Gender

−2.20

0.58

3067

−3.80

0.0001***

----

----

----

----

0.06*

Beck Depression Inventory (BDI)

0.2158

0.05522

3067

3.91

<.0001***

Years since enrollment*Age

0.1110

0.01615

3067

6.87

<.0001***

Gender

Effect for Placebo Sub-Group

+Years since enrollment

+Age

+Where there is an interaction the main effect is difficult to interpret and is not reported.
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